Effectiveness of Peripheral Intravenous Line Securement With Splint in Neonates
Effectiveness of Peripheral Intravenous Line Securement With Splint in Neonates Admitted to the Neonatal Intensive Care Unit.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan, 74200
- Dr. Ruth KM Pfau Civil Hospital/Dow University of Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Neonates
- Any gender
- Admitted to the NICU and required PIVC insertion
Exclusion Criteria:
- Skin conditions like fragile skin syndromes, dermatitis, or local infections that may worsen with splint and adhesive use
- Congenital limb deformities like clubfoot, polydactyly, joint contractures that impede proper splint application
- Severe limb edema
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group-A
Neonates were supported with a splint for PIVC securement.
|
Neonates were supported with a splint for PIVC securement.
|
|
Active Comparator: Group-B
Neonates were not supported with a splint for PIVC securement.
|
Neonates were not supported with a splint for PIVC securement.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dwell time
Time Frame: One week
|
The dwell time of PIVCs with and without splints was compared, calculated from PIVC insertion to the completion of the therapy.
|
One week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Zainab Khalid, Dr. Ruth KM Pfau Civil Hospital/Karachi, Dow University of Health Sciences, Karachi
- Study Director: Muhammad Rafique, FCPS, Dr. Ruth KM Pfau Civil Hospital, Karachi/Dow University of Health Sciences, Karachi
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Dr. Zainab-Karachi
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.